Compounds and uses thereof for the modulation of hemoglobin
US-9422279-B2 · Aug 23, 2016 · US
US11071725B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11071725-B2 |
| Application number | US-202015929436-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 1, 2020 |
| Priority date | Sep 19, 2018 |
| Publication date | Jul 27, 2021 |
| Grant date | Jul 27, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.
Opening claim text (preview).
We claim: 1. A process for preparing a compound of Formula I: comprising coupling compound 5 with 3-hydroxy-2-phenylpropanoic acid to afford the compound of Formula I: 2. The process of claim 1 , wherein compound 5 is obtained by a process comprising deprotecting compound 4 to afford compound 5: 3. The process of claim 2 , wherein compound 4 is obtained by a process comprising coupling compound 3 with tert-butyl 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-carboxylate to afford compound 4: 4. The process of claim 1 , wherein the compound of Formula I is Compound 1: 5. A compound selected from the group consisting of: 6. The compound of claim 5 , wherein the compound is: 7. The compound of claim 5 , wherein the compound is: 8. The process of claim 4 , comprising coupling compound 5 with (S)-3-hydroxy-2-phenylpropanoic acid to afford Compound 1: 9. A reaction mixture composition comprising: 2-[2H,3H-[1,4]dioxino[2,3-b]pyridine-7-sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole; 3-hydroxy-2-phenylpropanoic acid; and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluoro-phosphate (HATU). 10. The reaction mixture composition of claim 9 , wherein the 2-[2H,3H-[1,4]dioxino[2,3-b]pyridine-7-sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluoro-phosphate (HATU) are combined in a mole ratio of 1.0:2.0. 11. The reaction mixture composition of claim 9 , wherein the 2-[2H,3H-[1,4]dioxino[2,3-b]pyridine-7-sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole, 3-hydroxy-2-phenylpropanoic acid; and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluoro-phosphate (HATU) are combined in a mole ratio of 1.0:1.2:2.0. 12. The reaction mixture composition of claim 9 , further comprising (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one (Compound 1). 13. A reaction mixture composition comprising: 7-((3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)sulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine; (S)-3-hydroxy-2-phenylpropanoic acid; and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluoro-phosphate (HATU). 14. The reaction mixture composition of claim 13 , wherein the 7-((3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)sulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluoro-phosphate (HATU) are combined in a mole ratio of about 0.4:0.5. 15. The reaction mixture composition of claim 13 , wherein the 7-((3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)sulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine, (S)-3-hydroxy-2-phenylpropanoicacid, and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluoro-phosphate (HATU) are combined in a mole ratio of about 0.4:0.5:0.5. 16. The reaction mixture composition of claim 13 , further comprising (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one (Compound 1). 17. A process comprising an amide coupling of Compound 5 and tropic acid in the presence of 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluoro-phosphate (HATU) to generate a composition comprising (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one (Compound 1). 18. A process of preparing a composition comprising (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one (Compound 1), the process comprising the step of amide coupling of Compound 5 and tropic acid at a temperature of about 20 deg. C. in the presence of 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluoro-phosphate (HATU) to generate a composition comprising (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one (Compound 1). 19. The process of claim 18 , further comprising the steps of: a. treating 7-bromo-2H,3H-[1,4]dioxino[2,3-b]pyridine with a mixture of n-butyl lithium and dibutylmagnesium followed by sulfuryl chloride to give sulfonyl chloride 3: b. treating sulfonyl chloride 3 with tert-butyl 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-carboxylate in the presence of triethylamine (TEA) to obtain a Boc-protected monosulfonamide (Compound 4): c. treating Compound 4 with trifluoroacetic acid (TFA) to obtain Compound 5 20. A process comprising the step of combining compound 5 with (S)-3-hydroxy-2-phenylpropanoic acid and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluoro-phosphate (HATU) in a reaction mixture to obtain a composition comprising a PKR Activating Compound characterized by 1H NMR (400 MHz, DMSO-d6) δ 8.13 (d, J=2.0 Hz, 1H), 7.61 (d, J=2.0 Hz, 1H), 7.31-7.20 (m, 5H), 4.75 (t, J=5.2 Hz, 1H), 4.50-4.47 (m, 2H), 4.40-4.36 (m, 1H), 4.32-4.29 (m, 2H), 4.11-3.87 (m, 8H), 3.80-3.77 (m, 1H), 3.44-3.41 (m, 1H), LC-MS (ESI) m/z: calculated for C22H23N3O6S: 457.13; and 458.0 [M+H]+. 21. The process of claim 20 , wherein the reaction mixture is maintained at about 20 degrees C. to obtain the composition comprising the PKR Activating Compound.
Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose · CPC title
Antianaemics · CPC title
with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring · CPC title
the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin · CPC title
Ortho-condensed systems · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.